Apellis Pharmaceuticals, Inc. (BIT:1APLS)

Revenue

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
EMPAVELI Revenue	88.46M	98.09M	Log In	Log In	Log In
SYFOVRE Revenue	600.57M	611.86M	Log In	Log In	Log In
Total Product Revenue	689.03M	709.95M	Log In	Log In	Log In
Licensing and Other Revenue	65.62M	71.41M	Log In	Log In	Log In
Revenue (Other)	-1.00K	-	Log In	Log In	Log In
Revenue (Total)	754.65M	781.37M	Log In	Log In	Log In

Updated Jun 30, 2025. Data Source: Fiscal.ai.